Introduction
============

*Prohibitin* is a candidate tumor suppressor gene encoding a 30 kDa intracellular protein which regulates cell cycle progression in multiple cell types. It interacts with the retinoblastoma tumor suppressor protein and its family members to suppress E2F-mediated transcription, and binds to p53 protein, increasing p53 transcriptional activity via increased DNA binding.[@b1-ott-6-177],[@b2-ott-6-177] The human *prohibitin* gene is located on chromosome 17q21, a region of frequent loss of heterozygosity in breast cancers, spanning approximately 11 kb and consisting of seven exons.[@b3-ott-6-177] In total, 217 single nucleotide polymorphisms have been identified in the *prohibitin* gene region, and 38 nucleotide polymorphisms in the coding region (<http://www.ncbi.nlm.nih.gov/SNP/>). Of these, 14 nucleotide polymorphisms have been reported in the 3′-untranslated region, as shown in [Table 1](#t1-ott-6-177){ref-type="table"}, only five nucleotide polymorphisms (rs6917, rs9893420, rs111398671, rs112294663, rs73324369) have minor allele frequencies available, and the potential microRNA binding sites are summarized in [Table 1](#t1-ott-6-177){ref-type="table"}. The most extensively studied nucleotide polymorphism of *prohibitin* is a C-to-T transition at position 1630 in the 3′-untranslated region, that creates a variant with hsa-miR-1292 and hsa-miR-886-5p as potential binding sites (<http://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi>). This variant lacks antiproliferative activity and significantly reduces cell motility.[@b4-ott-6-177]--[@b6-ott-6-177]

Recent studies have evaluated the potential role of *prohibitin* in development of breast cancer and risk modification associated with *prohibitin* 1630 C\>T polymorphism, but there are still no consistent data to indicate the molecular mechanism of 1630 C\>T polymorphism in the regulation of *prohibitin* mRNA expression and its role in carcinogenesis. Although the T allele has been associated with an increased risk of breast cancer in women aged younger than 50 years who have a first-degree relative with breast cancer,[@b7-ott-6-177] there are other studies that have not found an association between this polymorphism and breast cancer. In order to evaluate this potential association more precisely, we identified all published case-control studies, amounting to 5072 cases and 4796 controls, and undertook a quantitative analysis to identify evidence of an association between *prohibitin* 1630 C\>T polymorphism and breast cancer risk.

Materials and methods
=====================

Genotype and mRNA expression data in lymphoblastoid cell lines
--------------------------------------------------------------

We used additional data on *prohibitin* genotypes and mRNA levels available online (<http://app3.titan.uio.no/biotools/help.php?app=snpexp>) for analysis of the genotype-phenotype relationship.[@b8-ott-6-177] We analyzed the variation in gene expression using genome-wide expression arrays (47,294 transcripts) from Epstein-Barr virus-transformed lymphoblastoid cell lines from the same 270 HapMap individuals.[@b9-ott-6-177] The genotyping data were from the HapMap Phase II release 23 data set consisting of 3.96 million single nucleotide polymorphism genotypes from 270 individuals in four populations.[@b10-ott-6-177]

Publication search and data extraction
--------------------------------------

Eligible studies were identified by searching in the PubMed, ISI Web of Knowledge, and Embase databases for relevant reports (last search update, August 2012), using the search terms "PHB" or "prohibitin", "polymorphism", and "breast cancer". We did not define any minimum number of patients to be included for meta-analysis. When multiple studies of the same patient population were identified, we included the published report with the largest sample size.

Inclusion criteria were: evaluation of prohibitin 1630 C\>T polymorphism and breast cancer risk, case-control study design, and sufficient published data for estimating an odds ratio (OR) with a 95% confidence interval (CI). Only the most recent or complete study was used if the same study subjects were included in more than one publication. The main exclusion criteria were: no control population, no available genotype frequency, and overlapping data.

Two authors reviewed the articles separately and extracted the data from all eligible publications according to the criteria listed above. Any discrepancies between investigators were resolved by discussion and consultation with a third reviewer. The first author's surname, year of publication, country of original ethnicity, study design, genotyping method, and numbers of genotyped cases and controls (CC, CT, and TT genotypes) were recorded for each study.

Statistical methods
-------------------

The genotype and phenotype relationship analysis was performed using SAS software (version 9.1, SAS Institute, Cary, NC). A pooled OR and 95% CI were calculated to estimate the risk of breast cancer associated with *prohibitin* 1630 C\>T. For all studies, we estimated the association under five different types of OR, namely the allele contrast model (T versus C), homozygote codominant model (TT versus CC), heterozygote codominant model (CT versus CC), dominant model (TT/CT versus CC), and recessive model (TT versus CC/CT). Hardy-Weinberg equilibrium was investigated using the χ^2^ test. The Q-statistic and *I*^2^ test were used to investigate the degree of heterogeneity between studies. When *P* ≥ 0.1 or *I*^2^ ≤ 50% indicated a lack of heterogeneity, the fixed-effects model (Mantel-Haenszel method) was used. Otherwise, the random-effects model (DerSimonian-Laird method) was chosen. Egger's test and inverted Begg's funnel plots were used to detect any publication bias. A sensitivity analysis was also performed by repeating the meta-analysis and omitting each study at each iteration.[@b11-ott-6-177],[@b12-ott-6-177] The data were analyzed using Revman 5.0 software (<http://ims.cochrane.org/revman>).

Results
=======

*Prohibitin* mRNA expression by genotype in lymphoblastoid cell lines
---------------------------------------------------------------------

We used the available HapMap-cDNA expression database for correlation analysis of prohibitin genotype and mRNA expression in 270 HapMap lymphoblastoid cell lines. Except for nine cell lines with no available values, 180 (68.9%) cell lines had the CC genotype, 71 (27.3%) had the CT genotype, and 10 (3.8%) had the TT genotype. [Figure 1](#f1-ott-6-177){ref-type="fig"} shows *prohibitin* mRNA expression according to 1630 C\>T genotype for the lymphoblastoid cell lines. There was no significant difference in *prohibitin* mRNA expression level between cell lines carrying the TT genotype (9.05 ± 0.31), TC genotype (9.04 ± 0.33), or CC genotype (8.96 ± 0.29, *P*~trend~ = 0.543, [Figure 1](#f1-ott-6-177){ref-type="fig"}).

Study characteristics
---------------------

After careful examination according to the inclusion criteria, six publications on polymorphisms of *prohibitin* 1630 C\>T and breast cancer risk were eligible,[@b4-ott-6-177],[@b7-ott-6-177],[@b13-ott-6-177]--[@b16-ott-6-177] of which the study by Jakubowska et al[@b14-ott-6-177] was reported twice. For the overlapping studies, only the one with the largest sample numbers was included. Jupe et al[@b7-ott-6-177] only provided information on C/T or T/T versus C/C. Hence, a total of five publications including 5072 cases and 4796 controls were used in the present meta-analysis. [Table 2](#t2-ott-6-177){ref-type="table"} lists the main characteristics of these studies. All cases were histologically confirmed as breast cancer, and controls were cancer-free and hospital-based populations matched for age and gender. The genotype distribution of the controls was in Hardy-Weinberg equilibrium, except for one study.[@b7-ott-6-177]

Meta-analysis results
---------------------

The results of the meta-analysis are shown in [Table 3](#t3-ott-6-177){ref-type="table"}. Because the between-study heterogeneity of each study included in our meta-analysis was not statistically significant, all pooled ORs were derived from fixed-effects models. We observed that the *prohibitin* 1630 C\>T polymorphism was significantly correlated with risk of breast cancer in the allele contrast model T versus C (OR 1.09, 95% CI 1.01--1.18, [Figure 2](#f2-ott-6-177){ref-type="fig"}), the homozygote codominant model TT versus CC (OR 1.47, 95% CI 1.12--1.92, [Figure 3](#f3-ott-6-177){ref-type="fig"}), and the recessive model TT versus CC/CT (OR 1.45, 95% CI 1.10--1.89, [Figure 4](#f4-ott-6-177){ref-type="fig"}). However, no significant association was detected for the heterozygote codominant model CT versus CC (OR 1.04, 95% CI 0.95--1.14, [Figure 5](#f5-ott-6-177){ref-type="fig"}) or the dominant model TT/CT versus CC (OR 1.08, 95% CI 0.99--1.18, [Figure 6](#f6-ott-6-177){ref-type="fig"}).

Publication bias
----------------

Funnel plots and Egger's test were used to assess publication bias in the literature. There was no evidence of publication bias for *prohibitin* 1630 C\>T polymorphism, and the results of the Egger's test suggested no publication bias for the allele contrast model (*P* = 0.685), homozygote codominant model (*P* = 0.810), heterozygote codominant model (*P* = 0.926), dominant model (*P* = 0.639), or recessive model (*P* = 0.846).

Discussion
==========

The 3′ untranslated region of the *prohibitin* gene which encodes a transacting regulatory RNA molecule arrests cell proliferation between the G~1~ and S phases of the cell cycle.[@b17-ott-6-177] Jupe et al confirmed the antiproliferative activity of prohibitin by microinjection of prohibitin mRNA and protein into normal and immortalized cancer cell lines.[@b18-ott-6-177] The protein-encoding region of the prohibitin gene was not found to be mutated, but the 3′-untranslated region of prohibitin mutations inhibited cell cycle progression in loss of human cancer cell lines.[@b5-ott-6-177] The investigators confirmed that a single nucleotide polymorphism (C--T transition) in the prohibitin 3′-untranslated region creates a null (T) allele whereby the RNA product has lost its antiproliferative activity.[@b17-ott-6-177] The results of our study are consistent with the functional *prohibitin* 3′-untranslated region 1630 C\>T polymorphism resulting in increased risk of breast cancer, although there was no significant association between *prohibitin* 1630 C\>T polymorphism and mRNA expression in lymphoblastoid cell lines from the HapMap database. Data being collected from different studies without stratification/adjustment for differences between studies and inconsistent use of selection criteria are possible explanations for this. Further investigations should be done in breast cancer tissue or cells to determine if a correlation exists between genotype and mRNA expression.

In this study, we investigated 5072 cases and 4796 controls, the allele contrast model, the homozygote codominant and the recessive model of prohibitin 1630 C\>T polymorphism were found to be significantly associated with influencing the risk of breast cancer. Heterogeneity and publication bias were not observed in this study. Our findings suggest that *prohibitin* 1630 C\>T polymorphism increases the risk of breast cancer.

Some limitations of this meta-analysis need to be acknowledged when interpreting its findings. First, we presumed that ethnicity status and family history play diverse roles in the risk of breast cancer. In our study, we considered the possibility that the effect of *prohibitin* 1630 C\>T polymorphism might be ethnicity-specific in mixed populations, but we did not perform subgroup analysis to detect an association between this polymorphism and ethnicity. Second, our results were based on unadjusted estimates, so a more precise analysis should be done when more detailed individual data become available. A recent study evaluated the association between genetic variants of *prohibitin* and breast cancer risk in BRCA1 or BRCA2 mutation carriers, and the findings showed that the *prohibitin* 1630TT genotype may modify breast cancer risk in these women.[@b16-ott-6-177] Third, as we all know, cancer is a complicated disease, different genetic backgrounds may contribute to the discrepancy, and it is still necessary to conduct larger sample studies considering gene-gene and gene-environment interactions, which may be an important component of the association between *prohibitin* 1630 C\>T polymorphism and risk of breast cancer. In conclusion, the results of this meta-analysis suggest that the *prohibitin* 1630 C\>T variant was associated with a significant increase in the risk of breast cancer.
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###### 

The SNPs of *prohibitin* 3′UTR and MicroRNA binding sites

  **Name**      **Chr position**   **Alleles**   **MAF**   **Potential MicroRNA binding sites**
  ------------- ------------------ ------------- --------- --------------------------------------
  rs6917        44836542           C/T           0.1924    hsa-miR-886-5p,hsa-miR-1292
  rs9893420     44836887           A/G           0.0151    hsa-miR-15a,hsa-miR-15b,hsa-miR-16
                                                           hsa-miR-103,hsa-miR-107,hsa-miR-195
                                                           hsa-miR-220c,hsa-miR-217,hsa-miR-424
                                                           hsa-miR-497,hsa-miR-873,hsa-miR-933
  rs111398671   47481589           C/T           0.0064    NA
  rs112294663   47481625           A/G           0.0172    NA
  rs73324369    47481676           C/T           0.0115    NA

**Abbreviations:** Chr, chromosome; MAF, Minor Alleles Frequency; Mi, micro; NA, not available; RNA, ribonucleic acid; SNP, single nucleotide polymorphism; UTR, untranslated region.

###### 

Characteristics of the studies included in the meta-analysis

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **First author**                   **Year**   **Country**   **Genotyping method**   **Source**   **Genotypes distribution (cases/controls)**   **HWE**                                                                                                              
  ---------------------------------- ---------- ------------- ----------------------- ------------ --------------------------------------------- ------------------------------------------------ ----- ------ ------------------------------------------------- ---- ------
  Jupe et al[@b7-ott-6-177]          2001       USA           PCR-RFLP                PB           128                                           77[^\*^](#tfn3-ott-6-177){ref-type="table-fn"}         709    337[^\*^](#tfn3-ott-6-177){ref-type="table-fn"}        NA

  Spurdle et al[@b13-ott-6-177]      2002       Australia     PCR-RFLP                PB           992                                           416                                              38    533    235                                               18   0.18

  Campbell et al[@b4-ott-6-177]      2003       UK            PCR-RFLP                PB           188                                           93                                               10    170    61                                                7    0.59

  Karakus et al[@b15-ott-6-177]      2008       Turkey        PCR-RFLP                PB           67                                            36                                               3     101    47                                                6    0.86

  Jakubowska et al[@b16-ott-6-177]   2012       Poland        iPLEX PCR-RFLP\         PB           2029                                          891                                              104   1771   747                                               54   0.02
                                                              Taqman                                                                                                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

For these just presenting the information for genotypes of CC and CT + TT, dominant model is calculated only.

**Abbreviations:** HWE, Hardy--Weinberg equilibrium; NA, not available; PB, population-based study; PCR, polymerase chain reaction.

###### 

Result of meta-analysis for *prohibitin* 3′UTR 1630 C\>T polymorphism and breast cancer risk

  **Study**   **T vs C**                                                            **TT vs CC**                                                          **CT vs CC**               **CT/TT vs CC**           **TT vs CT/CC**                                                
  ----------- -------------------------------------------------------------- ------ -------------------------------------------------------------- ------ ------------------- ------ ------------------- ----- -------------------------------------------------------------- ------
  Groups      OR (95% CI)                                                    Ph     OR (95% CI)                                                    Ph     OR (95% CI)         Ph     OR (95% CI)         Ph    OR (95% CI)                                                    Ph
  Total       1.09 (1.01--1.18)[^a^](#tfn6-ott-6-177){ref-type="table-fn"}   0.43   1.47 (1.12--1.92)[^a^](#tfn6-ott-6-177){ref-type="table-fn"}   0.51   1.04 (0.95--1.14)   0.38   1.08 (0.99--1.18)   0.4   1.45 (1.10--1.89)[^a^](#tfn6-ott-6-177){ref-type="table-fn"}   0.49

**Notes:**

Statistically significant result; Ph: *P* value of Q test for heterogeneity.

**Abbreviations:** CI, Confidence Interval; OR, Odds Ratio; UTR, Untranslated Regions.
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